(Q39497921)

12 September 2017

title

Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines (English)

1 reference

12 September 2017

1 reference

Laurent Brard

1

1 reference

12 September 2017

Thilo S Lange

2

1 reference

12 September 2017

Katina Robison

3

1 reference

12 September 2017

Kyu Kwang Kim

4

1 reference

12 September 2017

Tahniyath Ara

5

1 reference

12 September 2017

Megan Marie McCallum

6

1 reference

12 September 2017

Leggy A Arnold

7

1 reference

12 September 2017

Richard G Moore

8

1 reference

12 September 2017

Rakesh K Singh

9

1 reference

12 September 2017

language of work or name

English

0 references

publication date

30 July 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

123

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

370-378

1 reference

Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population.

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Vitamin D signalling pathways in cancer: potential for anticancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Quantification of the vitamin D receptor-coregulator interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Vitamin D and vitamin D analogs as cancer chemopreventive agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Cyclins and cell cycle checkpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Expression and function of the insulin receptor substrate proteins in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

MEK inhibition enhances paclitaxel-induced tumor apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

IRS-4 mediates protein kinase B signaling during insulin stimulation without promoting antiapoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.07.002

10.1016/J.YGYNO.2011.07.002

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference